

# Computational Healthcare and Precision Medicine

***Wade L. Schulz, MD, PhD***

*Assistant Professor, Yale School of Medicine*

*Director of Informatics, Department of Laboratory Medicine*

*Director, CORE Center for Computational Health, Yale New Haven Hospital*




Yale SCHOOL OF MEDICINE

YaleNewHavenHealth


01000011011001010111  
00111010001100 01011100  
10001000000110 11001101  
1110110000000000  
10001  
00 101101111011011011  
10 000111010101110101  
10 001011101000110101  
1101111111011100001  
011011000001000 00100100  
00110010001100 01011011  
00011101000110100000000

Center for  
Computational  
Health

# Goal: Precision Diagnostics and Therapy



# Precision Medicine at Yale/YNHH



# An Example: Pharmacogenomic Screening

News > Medscape Medical News > Oncology News

## After Fatal Toxicity, Questions Over DPD Testing Before Chemo

Pam Harrison

March 13, 2019



Read Comments



+ ADD TO EMAIL ALERTS

Some cancer patients react very badly to commonly used chemotherapies — but there is a test that can identify those patients.

So why isn't this test being used?

This is the question currently being asked in a courtroom, where the families of four patients who died are now suing the health authorities because testing was not carried out before treatment was initiated. The argument is that such testing could have potentially prevented these deaths.

This scenario comes from France and concerns testing for deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme or for certain polymorphisms of the *DPYD* gene that encodes for that enzyme.

# Barriers to Implementation


- Access to data to develop clinical evidence and guidelines
- Coverage to support routine or targeted clinical testing
- Ability to share results to increase cost-efficacy of testing
- Mechanism to deliver meaningful results at the point-of-care

# Pharmacogenomics at Yale/YNHH


- Project initiated in 2018 with panel-based test in 3 clinical populations
- Multi-disciplinary project (pharmacy, laboratory medicine, specialty-specific providers)

# Genomic Data Integration and Clinical Decision Support

- Genomic decision support at the point-of-care
  - Move beyond a text / PDF report
  - Deliver complex interpretations when needed clinically
  - Quickly find historical data



# Pilot Results of Testing





# Computational Healthcare Strategy



- Part of a larger strategy to develop a comprehensive computational health platform
  - Integrate genetic and phenotypic (clinical, patient-reported) data
  - Capacity to handle large volumes of data generated for precision medicine applications (genomics, radiology, digital pathology)
  - Ability to use advanced decision support and integrate with the EHR, but not be dependent on single vendor
  - Oversight of data generation and analytics to ensure patient safety in a rapidly evolving field

# Computational Healthcare and Precision Medicine

**Wade L. Schulz, MD, PhD**

*Assistant Professor, Yale School of Medicine*

*Director of Informatics, Department of Laboratory Medicine*

*Director, CORE Center for Computational Health, Yale New Haven Hospital*

*wade.schulz@yale.edu*



Yale SCHOOL OF MEDICINE

YaleNewHavenHealth

0100001101100101011011  
00111010001100 01011100  
10001000000110 11001101  
1110110000000000  
00 101101111011011011  
10 000111010101110101  
10 001011101000110101  
1101111111011100001  
011011000001000 00100100  
00110010011100 01011011  
00011101000110100000000

Center for  
Computational  
Health